Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,526 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan.
Goto H, Kitawaki T, Fujii N, Kato K, Onishi Y, Fukuhara N, Yamauchi T, Toratani K, Kobayashi H, Yoshida S, Shimo M, Onodera K, Senjo H, Onozawa M, Hirata K, Yokota I, Teshima T. Goto H, et al. Among authors: kobayashi h. Int J Clin Oncol. 2023 Jun;28(6):816-826. doi: 10.1007/s10147-023-02334-w. Epub 2023 Apr 18. Int J Clin Oncol. 2023. PMID: 37071252
Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Kobayashi H, Asada N, Egusa Y, Ikeda T, Sakamoto M, Abe M, Ennishi D, Sakata M, Takaki A, Kawahara S, Meguri Y, Nishimori H, Fujii N, Matsuoka KI, Sato Y, Yoshino T, Maeda Y. Kobayashi H, et al. Int J Hematol. 2021 Sep;114(3):401-407. doi: 10.1007/s12185-021-03157-z. Epub 2021 Apr 27. Int J Hematol. 2021. PMID: 33907976
Pretransplant nivolumab further enhanced Treg expansion after posttransplant cyclophosphamide; another aspect for immune tolerance by PTCy after nivolumab.
Ikegawa S, Meguri Y, Mizuhara K, Fukumi T, Kobayashi H, Sumii Y, Kondo T, Sando Y, Iwamoto M, Asada N, Ennishi D, Nishimori H, Fujii K, Fujii N, Fujisawa Y, Imai T, Maeda Y, Matsuoka KI. Ikegawa S, et al. Among authors: kobayashi h. Leukemia. 2021 Mar;35(3):929-931. doi: 10.1038/s41375-021-01167-8. Epub 2021 Feb 17. Leukemia. 2021. PMID: 33597730 No abstract available.
Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study.
Urata T, Naoi Y, Jiang A, Boyle M, Sunami K, Imai T, Nawa Y, Hiramatsu Y, Yamamoto K, Fujii S, Yoshida I, Yano T, Chijimatsu R, Murakami H, Ikeuchi K, Kobayashi H, Tani K, Ujiie H, Inoue H, Tomida S, Yamamoto A, Kondo T, Fujiwara H, Asada N, Nishimori H, Fujii K, Fujii N, Matsuoka KI, Sawada K, Momose S, Tamaru JI, Nishikori A, Sato Y, Yoshino T, Maeda Y, Scott DW, Ennishi D. Urata T, et al. Among authors: kobayashi h. Blood Adv. 2023 Dec 26;7(24):7459-7470. doi: 10.1182/bloodadvances.2023010402. Blood Adv. 2023. PMID: 37552496 Free PMC article.
Baseline total lesion glycolysis combined with interim positron emission tomography-computed tomography is a robust predictor of outcome in patients with peripheral T-cell lymphoma.
Kitadate A, Narita K, Fukumoto K, Terao T, Tsushima T, Kobayashi H, Abe Y, Miura D, Takeuchi M, Machida Y, Matsue K. Kitadate A, et al. Among authors: kobayashi h. Cancer Med. 2020 Aug;9(15):5509-5518. doi: 10.1002/cam4.3226. Epub 2020 Jun 18. Cancer Med. 2020. PMID: 32558387 Free PMC article.
9,526 results